Drugmaker Pfizer didn’t engage in off-label marketing of its cholesterol drug Lipitor, according to a federal appeals court ruling May 17 that affirmed a prior dismissal of a whistle-blower’s False Claims Act lawsuit (United States ex rel. Polansky v. Pfizer, Inc., 2016 BL 156070, 2d Cir., 14-4774, 5/17/16).
Whistle-blower Jesse Polansky, a former Pfizer medical director, said the drugmaker improperly marketed the drug to patients whose cholesterol levels and risk factors fell outside those outlined in the National Cholesterol Education Program Guidelines.
One of Polansky’s attorneys, Bruce J. Terris with Terris, Pravlik & Millian LLP in Washington ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.